Home/Pipeline/eOPN3‑Drug‑Resistant Epilepsy

eOPN3‑Drug‑Resistant Epilepsy

Drug‑Resistant Epilepsy

PreclinicalActive

Key Facts

Indication
Drug‑Resistant Epilepsy
Phase
Preclinical
Status
Active
Company

About Modulight Bio

Israeli optogenetics biotech leveraging light‑controlled GPCRs to treat refractory neurological disorders.

View full company profile

Other Drug‑Resistant Epilepsy Drugs

DrugCompanyPhase
Minder iCEMEpiminderPhase 2